Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01001910 · ClinicalTrials.gov registry record · Phase 2
Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Phase 2 study, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT01001910 is a Phase 2 study that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 22 participants.
The verdict
NCT01001910, a Phase 2 study, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This phase II trial studies how well pemetrexed disodium and carboplatin work in treating patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Drugs used in chemotherapy, such as pemetrexed disodium and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Interventions
- DRUG Carboplatin
- OTHER Laboratory Biomarker Analysis
- DRUG Pemetrexed Disodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2008-07 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01001910
The ClinicalTrials.gov registry entry for NCT01001910 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT01001910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01001910 about?
NCT01001910 is a clinical study titled "Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer". This phase II trial studies how well pemetrexed disodium and carboplatin work in treating patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Drugs used in chemotherapy, such as pemetrexed disodium and carboplatin, work in different ways to stop the growth of tumor cells, ...
What is the current status of trial NCT01001910?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2008-07. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01001910?
The interventions under investigation include: Carboplatin (DRUG), Laboratory Biomarker Analysis (OTHER), Pemetrexed Disodium (DRUG).
Who is sponsoring clinical trial NCT01001910?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.